Bilaketaren emaitzak - Dylan Conklin

  • Erakusten 1 - 9 emaitzak -- 9
Findu emaitzak
  1. 1
    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro nork Richard S. Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J. Cohen, Amrita J. Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J. Slamon

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

    Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer nork Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

    Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib nork Ondrej Kalous, Dylan Conklin, Amrita J. Desai, Neil A. O’Brien, Charles Ginther, Lee Anderson, David J. Cohen, Carolyn D. Britten, Ian W. Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT nork Neil A. O’Brien, K McDonald, Tong Luo, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer

    Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer nork Neil A. O’Brien, Dylan Conklin, Richard P. Beckmann, Tong Luo, Kevin Chau, Josh D. Thomas, Ann Mc Nulty, Christophe C. Marchal, Ondrej Kalous, Erika von Euw, Sara A. Hurvitz, Colleen Mockbee, Dennis J. Slamon

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer nork Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

    Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines nork Eniko Papp, Dorothy Hallberg, Gottfried E. Konecny, Daniel C. Bruhm, Vilmos Adleff, Michaël Noë, Ioannis Kagiampakis, Doreen N. Palsgrove, Dylan Conklin, Yasuto Kinose, James R. White, Michael F. Press, Ronny Drapkin, Hariharan Easwaran, Stephen B. Baylin, Dennis J. Slamon, Victor E. Velculescu, Robert B. Scharpf

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis

    Concise total syntheses of (–)-jorunnamycin A and (–)-jorumycin enabled by asymmetric catalysis nork Eric R. Welin, Aurapat Ngamnithiporn, Max Klatte, Guillaume Lapointe, Gerit Pototschnig, Martina S.J. McDermott, Dylan Conklin, Christopher D. Gilmore, Pamela M. Tadross, Christopher K. Haley, Kenji Negoro, Emil Glibstrup, Christian U. Grünanger, Kevin M. Allan, Scott C. Virgil, Dennis J. Slamon, Brian M. Stoltz

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

    Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays nork Jun Li, Wei Zhao, Rehan Akbani, Wenbin Liu, Zhenlin Ju, Shiyun Ling, Christopher P. Vellano, Paul Roebuck, Qinghua Yu, Agda Karina Eterovic, Lauren A. Byers, Michael A. Davies, Wanleng Deng, Y.N. Vashisht Gopal, Guo Chen, Erika M. von Euw, Dennis J. Slamon, Dylan Conklin, John V. Heymach, Adi F. Gazdar, John D. Minna, Jeffrey N. Myers, Yiling Lu, Gordon B. Mills, Han Liang

    Argitaratua 2017
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: